SCHEMBL5201813

SCHEMBL5201813

CCCc1c2c(nn1C)C(=O)[N]C(c1cc(C(=O)N3CCN(C)CC3)ccc1OCC)=N2

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.41
HPGD P15428 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALOX15 P16050 1/20 0.39
KMT2A Q03164 1/20 0.39
LRRK2 Q5S007 3/20 0.38
PDE5A O76074 3/20 0.37
PDE6C P51160 2/20 0.37
USP2 O75604 2/20 0.37
HSD17B10 Q99714 1/20 0.37
GLA P06280 1/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1913406 0.82 PDE5A (0.55) HPGDKMT2APDE5APDE6CHSD17B10
SCHEMBL3453681 0.82 PDE5A (0.53) PDE5APDE6CCA12CA9
SCHEMBL6638843 0.77 PDE5A (0.54) KMT2APDE5APDE6CHSD17B10LMNA
SCHEMBL7449440 0.75 PDE5A (0.56) PDE5APDE6CCA12CA9
SCHEMBL5078828 0.75 PDE5A (0.33) HPGDKMT2APDE5APDE6C
SCHEMBL7368938 0.73 KMT2A (0.30) HPGDKMT2APDE5A
SCHEMBL5076135 0.70 PDE5A (0.54) PDE5A
SCHEMBL145682 0.69 PDE5A (0.77) HPGDKMT2APDE5APDE6C
SCHEMBL29707546 0.69 PDE5A (0.77) HPGDKMT2APDE5APDE6C
SCHEMBL8344627 0.67 PDE5A (0.70) PDE5APDE6C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0702555-A1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE Pfizer Limited (GB) 1996-03-27 EP claimed
WO-1994028902-A1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE PFIZER LIMITED (GB) 1994-12-22 WO claimed
EP-1868590-A2 METHOD OF INCREASING TESTOSTERONE AND RELATED STEROID CONCENTRATIONS IN WOMEN Unimed Pharmaceuticals, Inc. (US) 2007-12-26 EP disclosed
WO-2006113242-A2 METHOD OF INCREASING TESTOSTERONE AND RELATED STEROID CONCENTRATIONS IN WOMEN UNIMED PHARMACEUTICALS, INC. (US) 2006-10-26 WO disclosed
EP-1404343-A4 THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES SOLVAY PHARMACEUTICALS INC (US) 2006-08-02 EP disclosed
EP-1404343-A2 THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES Solvay Pharmaceuticals, Inc. (US) 2004-04-07 EP disclosed
EP-1315502-A1 METHOD FOR TREATING ERECTILE DYSFUNCTION AND INCREASING LIBIDO IN MEN Unimed Pharmaceuticals Inc. (US) 2003-06-04 EP disclosed
WO-2003002123-A2 THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES SOLVAY PHARMACEUTICALS, INC. (US) 2003-01-09 WO disclosed
WO-2002017927-A1 METHOD FOR TREATING ERECTILE DYSFUNCTION AND INCREASING LIBIDO IN MEN UNIMED PHARMACEUTICALS, INC. (US) 2002-03-07 WO disclosed
EP-0702555-A1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE Pfizer Limited (GB) 1996-03-27 EP disclosed
WO-1994028902-A1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE PFIZER LIMITED (GB) 1994-12-22 WO disclosed